0001415889-23-001757.txt : 20230201 0001415889-23-001757.hdr.sgml : 20230201 20230201215012 ACCESSION NUMBER: 0001415889-23-001757 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230130 FILED AS OF DATE: 20230201 DATE AS OF CHANGE: 20230201 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Brophy Michael Burkes CENTRAL INDEX KEY: 0001697362 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37478 FILM NUMBER: 23578653 MAIL ADDRESS: STREET 1: 201 INDUSTRIAL ROAD, SUITE 410 CITY: SAN CARLOS STATE: CA ZIP: 94070 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Natera, Inc. CENTRAL INDEX KEY: 0001604821 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 010894487 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 13011 MCCALLEN PASS STREET 2: BUILDING A SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78753 BUSINESS PHONE: 650-249-9090 MAIL ADDRESS: STREET 1: 13011 MCCALLEN PASS STREET 2: BUILDING A SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78753 4 1 form4-02012023_090202.xml X0306 4 2023-01-30 0001604821 Natera, Inc. NTRA 0001697362 Brophy Michael Burkes C/O NATERA, INC. 13011 MCCALLEN PASS BUILDING A SUITE 100 AUSTIN TX 78753 false true false false CHIEF FINANCIAL OFFICER Common Stock 2023-01-30 4 S 0 47188 42.0494 D 105499 D Common Stock 2023-01-30 4 S 0 1509 43.14 D 103990 D Common Stock 2023-01-31 4 S 0 35000 42.3303 D 68990 D Common Stock 2023-02-01 4 S 0 4761 42.8053 D 64229 D Common Stock 2023-02-01 4 S 0 10413 43.8110 D 53816 D Common Stock 2023-02-01 4 S 0 4152 44.3526 D 49664 D The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 4, 2022. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.0396 to $42.1307 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.3323 to $42.3275 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.24 to $43.22 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.24 to $44.23 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.24 to $44.59 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Tami Chen, Attorney-in-Fact 2023-02-01